1 research outputs found
Π Π°Π½Π½ΠΈΠ΅ ΠΈΠ·ΠΌΠ΅Π½Π΅Π½ΠΈΡ ΠΊΠ»ΠΈΠ½ΠΈΠΊΠΎ-Π»Π°Π±ΠΎΡΠ°ΡΠΎΡΠ½ΡΡ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»Π΅ΠΉ Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ², ΡΠΌΠ΅ΡΡΠΈΡ ΠΎΡ COVID-19
261,435,768 COVID-19 infections were detected worldwide, of them 5,207,634 deaths were registered. Identifying markers of the patient severity early in the course of the disease can facilitate the assessment of the risk of adverse outcome.The objective: To compare values of laboratory parameters and their changes during treatment of patients with a complicated course of COVID-19 infection.Subjects and Methods. 56 patients were included in the study, all of them were hospitalized to COVID Hospital of the Clinic of Bashkir State Medical University, Russian Ministry of Health, from September 30, 2021 to November 15, 2021, and their complicated course of the disease necessitated transfer to the intensive care unit (ICU). The laboratory evaluation included the following: a general blood and urine counts, blood chemistry including urea and creatinine, liver transaminases, and blood coagulogram (prothrombin time (PTT), prothrombin index (PTI), thrombin time, fibrinogen, and blood clotting time).Results. In the group of patients with a fatal outcome on the day of transfer to ICU, lymphocytopenia, eosinopenia, elevated values of creatinine, total bilirubin, transaminases, C-reactive protein, D-dimer, and ferritin were noted. Also on this day, microscopic hematuria, proteinuria and cylindruria were detected in the urine tests of most patients in this group during treatment.Conclusion. Critical deviations in the results of hematological and biochemical tests were revealed. Particular attention should be paid to such parameters as the level of erythrocytes, lymphocytes, eosinophils, glucose, urea, creatinine, total bilirubin, aspartate aminotransferase, alanine aminotransferase, creatine kinase, C-reactive protein, D-dimer, and ferritin.ΠΠΎ Π΄Π°Π½Π½ΡΠΌ Π½Π° 01.12.2021 Π³., Π²ΠΎ Π²ΡΠ΅ΠΌ ΠΌΠΈΡΠ΅ Π²ΡΡΠ²Π»Π΅Π½ΠΎ 261 435 768 Π·Π°Π±ΠΎΠ»Π΅Π²ΡΠΈΡ
COVID-19, ΠΈΠ· ΠΊΠΎΡΠΎΡΡΡ
5 207 634 ΡΠΌΠ΅ΡΠ»ΠΈ. ΠΡΡΠ²Π»Π΅Π½ΠΈΠ΅ ΠΌΠ°ΡΠΊΠ΅ΡΠΎΠ² ΡΡΠΆΠ΅ΡΡΠΈ ΡΠΎΡΡΠΎΡΠ½ΠΈΡ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Π½Π° ΡΠ°Π½Π½ΠΈΡ
ΡΡΠΎΠΊΠ°Ρ
Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ ΠΌΠΎΠΆΠ΅Ρ ΠΎΠ±Π»Π΅Π³ΡΠΈΡΡ ΠΎΡΠ΅Π½ΠΊΡ ΡΠΈΡΠΊΠ° Π½Π΅Π±Π»Π°Π³ΠΎΠΏΡΠΈΡΡΠ½ΠΎΠ³ΠΎ ΠΈΡΡ
ΠΎΠ΄Π°.Π¦Π΅Π»Ρ: ΡΡΠ°Π²Π½ΠΈΡΡ Π·Π½Π°ΡΠ΅Π½ΠΈΡ Π»Π°Π±ΠΎΡΠ°ΡΠΎΡΠ½ΡΡ
ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»Π΅ΠΉ ΠΈ ΠΈΡ
Π΄ΠΈΠ½Π°ΠΌΠΈΠΊΡ Π² ΠΏΡΠΎΡΠ΅ΡΡΠ΅ Π»Π΅ΡΠ΅Π½ΠΈΡ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΠΎΡΠ»ΠΎΠΆΠ½Π΅Π½Π½ΡΠΌ ΡΠ΅ΡΠ΅Π½ΠΈΠ΅ΠΌ COVID-19.ΠΠ°ΡΠ΅ΡΠΈΠ°Π» ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ: Π² ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΈ ΠΏΡΠΈΠ½ΡΠ»ΠΈ ΡΡΠ°ΡΡΠΈΠ΅ 56 ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ², Π³ΠΎΡΠΏΠΈΡΠ°Π»ΠΈΠ·ΠΈΡΠΎΠ²Π°Π½Π½ΡΡ
Π² ΠΊΠΎΠ²ΠΈΠ΄-Π³ΠΎΡΠΏΠΈΡΠ°Π»Ρ ΠΊΠ»ΠΈΠ½ΠΈΠΊΠΈ Π€ΠΠΠΠ£ ΠΠ Β«ΠΠΠΠ£Β» ΠΠΈΠ½Π·Π΄ΡΠ°Π²Π° Π ΠΎΡΡΠΈΠΈ Ρ 30.09.2021 Π³. ΠΏΠΎ 15.11.2021 Π³., ΠΎΡΠ»ΠΎΠΆΠ½Π΅Π½Π½ΠΎΠ΅ ΡΠ΅ΡΠ΅Π½ΠΈΠ΅ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ ΠΊΠΎΡΠΎΡΡΡ
Π²ΡΠ·Π²Π°Π»ΠΎ Π½Π΅ΠΎΠ±Ρ
ΠΎΠ΄ΠΈΠΌΠΎΡΡΡ ΠΏΠ΅ΡΠ΅Π²ΠΎΠ΄Π° Π² ΠΎΡΠ΄Π΅Π»Π΅Π½ΠΈΠ΅ ΡΠ΅Π°Π½ΠΈΠΌΠ°ΡΠΈΠΈ ΠΈ ΠΈΠ½ΡΠ΅Π½ΡΠΈΠ²Π½ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ (ΠΠ ΠΠ’). ΠΠ±ΡΠ΅ΠΌ Π»Π°Π±ΠΎΡΠ°ΡΠΎΡΠ½ΠΎΠ³ΠΎ ΠΎΠ±ΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ: ΠΎΠ±ΡΠΈΠΉ Π°Π½Π°Π»ΠΈΠ· ΠΊΡΠΎΠ²ΠΈ ΠΈ ΠΌΠΎΡΠΈ, Π±ΠΈΠΎΡ
ΠΈΠΌΠΈΡΠ΅ΡΠΊΠΈΠΉ Π°Π½Π°Π»ΠΈΠ· ΠΊΡΠΎΠ²ΠΈ Ρ ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΠ΅ΠΌ ΡΡΠΎΠ²Π½Π΅ΠΉ ΠΌΠΎΡΠ΅Π²ΠΈΠ½Ρ ΠΈ ΠΊΡΠ΅Π°ΡΠΈΠ½ΠΈΠ½Π°, ΠΏΠ΅ΡΠ΅Π½ΠΎΡΠ½ΡΡ
ΡΡΠ°Π½ΡΠ°ΠΌΠΈΠ½Π°Π·, ΠΊΠΎΠ°Π³ΡΠ»ΠΎΠ³ΡΠ°ΠΌΠΌΠ° ΠΊΡΠΎΠ²ΠΈ (ΠΏΡΠΎΡΡΠΎΠΌΠ±ΠΈΠ½ΠΎΠ²ΠΎΠ΅ Π²ΡΠ΅ΠΌΡ, ΠΏΡΠΎΡΡΠΎΠΌΠ±ΠΈΠ½ΠΎΠ²ΡΠΉ ΠΈΠ½Π΄Π΅ΠΊΡ, ΡΡΠΎΠΌΠ±ΠΈΠ½ΠΎΠ²ΠΎΠ΅ Π²ΡΠ΅ΠΌΡ, ΡΠΈΠ±ΡΠΈΠ½ΠΎΠ³Π΅Π½, Π²ΡΠ΅ΠΌΡ ΡΠ²Π΅ΡΡΡΠ²Π°Π½ΠΈΡ ΠΊΡΠΎΠ²ΠΈ).Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. Π Π³ΡΡΠΏΠΏΠ΅ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ Π»Π΅ΡΠ°Π»ΡΠ½ΡΠΌ ΠΈΡΡ
ΠΎΠ΄ΠΎΠΌ Π² Π΄Π΅Π½Ρ ΠΏΠ΅ΡΠ΅Π²ΠΎΠ΄Π° Π² ΠΠ ΠΠ’ ΠΎΡΠΌΠ΅ΡΠ΅Π½Ρ Π»ΠΈΠΌΡΠΎΡΠΈΡΠΎΠΏΠ΅Π½ΠΈΡ, ΡΠΎΠ·ΠΈΠ½ΠΎΠΏΠ΅Π½ΠΈΡ, ΠΏΠΎΠ²ΡΡΠ΅Π½Π½ΡΠ΅ Π·Π½Π°ΡΠ΅Π½ΠΈΡ ΠΊΡΠ΅Π°ΡΠΈΠ½ΠΈΠ½Π°, ΠΎΠ±ΡΠ΅Π³ΠΎ Π±ΠΈΠ»ΠΈΡΡΠ±ΠΈΠ½Π°, ΡΡΠ°Π½ΡΠ°ΠΌΠΈΠ½Π°Π·, Π‘-ΡΠ΅Π°ΠΊΡΠΈΠ²Π½ΠΎΠ³ΠΎ Π±Π΅Π»ΠΊΠ°, D-Π΄ΠΈΠΌΠ΅ΡΠ° ΠΈ ΡΠ΅ΡΡΠΈΡΠΈΠ½Π°. Π’Π°ΠΊΠΆΠ΅ Π² ΡΡΠΎΡ Π΄Π΅Π½Ρ Π² Π°Π½Π°Π»ΠΈΠ·Π°Ρ
ΠΌΠΎΡΠΈ Ρ Π±ΠΎΠ»ΡΡΠΈΠ½ΡΡΠ²Π° ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Π΄Π°Π½Π½ΠΎΠΉ Π³ΡΡΠΏΠΏΡ Π² Ρ
ΠΎΠ΄Π΅ Π»Π΅ΡΠ΅Π½ΠΈΡ Π±ΡΠ»ΠΈ ΠΎΠ±Π½Π°ΡΡΠΆΠ΅Π½Ρ ΠΌΠΈΠΊΡΠΎΡΠΊΠΎΠΏΠΈΡΠ΅ΡΠΊΠ°Ρ Π³Π΅ΠΌΠ°ΡΡΡΠΈΡ, ΠΏΡΠΎΡΠ΅ΠΈΠ½ΡΡΠΈΡ ΠΈ ΡΠΈΠ»ΠΈΠ½Π΄ΡΡΡΠΈΡ.ΠΠ°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅. ΠΡΡΠ²Π»Π΅Π½Ρ ΠΊΡΠΈΡΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΎΡΠΊΠ»ΠΎΠ½Π΅Π½ΠΈΡ Π² ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΠ°Ρ
Π³Π΅ΠΌΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ
, Π±ΠΈΠΎΡ
ΠΈΠΌΠΈΡΠ΅ΡΠΊΠΈΡ
Π°Π½Π°Π»ΠΈΠ·ΠΎΠ². ΠΡΠΎΠ±ΠΎΠ΅ Π²Π½ΠΈΠΌΠ°Π½ΠΈΠ΅ Π΄ΠΎΠ»ΠΆΠ½ΠΎ Π±ΡΡΡ ΡΠ΄Π΅Π»Π΅Π½ΠΎ ΡΠ°ΠΊΠΈΠΌ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»ΡΠΌ, ΠΊΠ°ΠΊ ΡΡΠΎΠ²Π΅Π½Ρ ΡΡΠΈΡΡΠΎΡΠΈΡΠΎΠ², Π»ΠΈΠΌΡΠΎΡΠΈΡΠΎΠ², ΡΠΎΠ·ΠΈΠ½ΠΎΡΠΈΠ»ΠΎΠ², Π³Π»ΡΠΊΠΎΠ·Ρ, ΠΌΠΎΡΠ΅Π²ΠΈΠ½Ρ, ΠΊΡΠ΅Π°ΡΠΈΠ½ΠΈΠ½Π°, ΠΎΠ±ΡΠ΅Π³ΠΎ Π±ΠΈΠ»ΠΈΡΡΠ±ΠΈΠ½Π°, Π°ΡΠΏΠ°ΡΡΠ°ΡΠ°ΠΌΠΈΠ½ΠΎΡΡΠ°Π½ΡΡΠ΅ΡΠ°Π·Ρ, Π°Π»Π°Π½ΠΈΠ½Π°ΠΌΠΈΠ½ΠΎΡΡΠ°Π½ΡΡΠ΅ΡΠ°Π·Ρ, ΠΊΡΠ΅Π°ΡΠΈΠ½ΠΊΠΈΠ½Π°Π·Ρ, Π‘-ΡΠ΅Π°ΠΊΡΠΈΠ²Π½ΠΎΠ³ΠΎ Π±Π΅Π»ΠΊΠ°, D-Π΄ΠΈΠΌΠ΅ΡΠ°, ΡΠ΅ΡΡΠΈΡΠΈΠ½Π°